195 related articles for article (PubMed ID: 21132644)
1. [Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
Mascia S; Garofalo C; Donnarumma G; Di Pietro R; Liberti ME; Pacilio M; Sagliocca A; Zamboli P; Minutolo R; Conte G; De Nicola L
G Ital Nefrol; 2010; 27(6):616-28. PubMed ID: 21132644
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
4. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
5. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
[TBL] [Abstract][Full Text] [Related]
6. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency.
Trakarnvanich T; Chalapipat O; Disthabanchong S; Kurathong S; Praditpornsilpa K; Stitchantrakul W; Chailurkit LO
J Med Assoc Thai; 2010 Aug; 93(8):885-91. PubMed ID: 20718162
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
8. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
[TBL] [Abstract][Full Text] [Related]
9. Paricalcitol reduces proteinuria in non-dialysis chronic kidney disease patients.
Hojs N; Bevc S; Balon BP; Hojs R; Ekart R
Ther Apher Dial; 2013 Aug; 17(4):368-72. PubMed ID: 23931873
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
Blair D; Byham-Gray L; Lewis E; McCaffrey S
J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
[TBL] [Abstract][Full Text] [Related]
13. Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.
Bellasi A; Galassi A; Salvi P; Cozzolino M
Blood Purif; 2013; 36(1):12-6. PubMed ID: 23736115
[TBL] [Abstract][Full Text] [Related]
14. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
Covic A; Voroneanu L; Goldsmith D
Nephron Clin Pract; 2010; 116(3):c187-95. PubMed ID: 20606478
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of secondary hyperparathyroidism in dialysis patients].
Di Luca M
G Ital Nefrol; 2009; 26 Suppl 49():S36-48. PubMed ID: 19941277
[TBL] [Abstract][Full Text] [Related]
16. [Guidelines for vitamin D prescription in dialysis patients].
Jean G; Lafage-Proust MH; Massy ZA; Drüeke TB
Nephrol Ther; 2009 Nov; 5(6):520-32. PubMed ID: 19748843
[TBL] [Abstract][Full Text] [Related]
17. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
18. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
Ravera M; Paoletti E
Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
[TBL] [Abstract][Full Text] [Related]
19. [Experience with active vitamin D metabolites in phosphorus-calcium metabolic disorders in patients with predialysis chronic kidney disease].
Milovanova LIu; Dobrosmyslov IA; Milovanov IuS
Ter Arkh; 2014; 86(6):52-6. PubMed ID: 25095656
[TBL] [Abstract][Full Text] [Related]
20. Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.
Sánchez-Álvarez JE; Rodríguez-Suárez C; Coronel-Aguilar D; González-Díaz I; Núñez-Moral M; Peláez-Requejo B; Fernández-Viña A; Quintana-Fernández A
Nefrologia; 2013 Jan; 33(1):70-6. PubMed ID: 23364628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
